MCM PRV Reauthorization Act

The MCM PRV Reauthorization Act extends the deadline for a priority review program that accelerates the approval of medical treatments for threats like bioterrorism agents, from 2023 to 2033. It amends the Federal Food, Drug, and Cosmetic Act to update the expiration date in Section 565A(g), maintaining the existing process for expediting reviews of medical countermeasures. This change directly affects drug manufacturers developing treatments for national security threats and the FDA, which administers the priority review pathway. The bill does not alter the program's criteria or scope but ensures continued support for these critical medical countermeasures through 2033.